(Reuters) -Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial ...

Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...